Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
This article was originally published in The Tan Sheet
Executive Summary
Significantly lower sales of GlaxoSmithKline's alli OTC weight-loss drug combined with struggles in the nicotine replacement therapy category weighed down the consumer health care division's performance in the firm's latest quarter
You may also be interested in...
GlaxoSmithKline's OTC Garage Sale Includes alli, FiberChoice
GlaxoSmithKline includes the alli weight-loss brand in its planned divestment of international OTCs worth about $813 million in 2010 sales, or 10% of the firm's total Consumer Healthcare business.
GSK’s Alli Marketing Plays Celebrity Endorsement Tune
Recording artist Wynonna Judd sings the praises of GlaxoSmithKline's weight-loss drug alli in a new marketing campaign
Alli Pioneers EU Centralized Process For Nonprescription Switch
The European Medicines Agency's clearance of GlaxoSmithKline's weight-loss drug alli for nonprescription status across the European Union marks the first success for a centralized Rx-to-OTC switch process